readthroughSign in
Nov 12, 2026Weekly roundupUpdated

Novo Nordisk registers four Phase 3 AMBITION trials for zenagamtide in type 2 diabetes

The company added AMBITION 1 through 4, testing zenagamtide against placebo and semaglutide, alongside its ongoing Phase 1 study of NNC9836-0001.

Novo Nordisk A/S posted four new Phase 3 trial registrations this week for its investigational drug zenagamtide, plus an update from its ongoing early-stage NNC9836-0001 study.

  • AMBITION 1 (NCT07931495) is a Phase 3 study comparing zenagamtide to placebo in participants with type 2 diabetes inadequately controlled on diet and exercise. The trial is listed as not yet recruiting, with an estimated enrollment of 200 participants1, and an estimated start date of 2026-11-10.
  • AMBITION 2 (NCT07931547) is a Phase 3 study testing zenagamtide against placebo in participants who have both type 2 diabetes and chronic kidney disease. Eligible participants must be on a stable once-daily dose of basal insulin, alone or in combination with metformin, SGLT2 inhibitors, or both, prior to screening2. The study is not yet recruiting, with an estimated enrollment of 450 participants2.
  • AMBITION 3 (NCT07931573) is a Phase 3 study testing higher dose levels of zenagamtide against semaglutide in participants with type 2 diabetes on metformin, SGLT2 inhibitors, or both. The trial is not yet recruiting, with an estimated enrollment of 1200 participants3, and includes a placebo arm matched to both active drugs.
  • AMBITION 4 (NCT07931599) is a Phase 3 study testing lower dose levels of zenagamtide against semaglutide in the same metformin/SGLT2i population. The study is not yet recruiting, with an estimated enrollment of 1060 participants4.
  • The Phase 1 study of NNC9836-0001, described as a new medicine aimed to treat type 2 diabetes5, remains recruiting, with an actual start date of 2026-10-22 and an estimated enrollment of 121 participants5 at a single site in Neuss, Germany. The record's last update was posted 2026-11-10.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.